Annals of Oncology 9:589-600, 1998
© 1998 European Society for Medical Oncology
review-article |
Malignant glioma: Should chemotherapy be overthrown by experimental treatments?
1Division of Medical Oncology, University Hospital Geneva, Switzerland
2Department of Neurosurgery, University Hospital Geneva, Switzerland
Correspondence to: Dr. P.-Y. Dietrich, PD Division of Medical Oncology, University Hospital, CH-1211 Geneva 14, Switzerland, E-mail: pierre-yves.dietrich{at}hcuge.ch
Despite more than two decades of clinical research with chemotherapy, the outcome of malignant gliomas remains poor. Recent years have seen major advances in elucidation of the biology of these tumors, which in turn have led to the current development of innovative therapeutic strategies. The question confronting us at the end of the 1990s is whether we should continue to use and investigate chemotherapy or whether the time has come for experimental treatments.
As a contribution to this debate, we reviewed the abundant literature on chemotherapy of malignant glioma, paying special attention to methodological features. The new treatment approaches based on current knowledge about glioma biology are then briefly summarized.
Assessment of more than 20 years of chemotherapy trials is discouraging despite a few areas of modest success. Only patients with specific histology (oligodendroglioma, anaplastic astrocytoma) and good prognostic factors (young age, good performance status) may benefit from chemotherapy, with a possible reversal of neurological dysfunction. However, the real impact on survival is small (anaplastic astrocytoma) or undefined (oligodendroglioma). Furthermore, it is unfortunately obvious that the outcome of glioblastoma patients is not significantly modified by chemotherapy. We believe the time has come to explore the potential of novel biological therapies in glioblastoma patients. This could also be proposed for anaplastic astrocytoma and oligodendroglioma patients after failure of chemotherapy.
brain neoplasms, chemotherapy, gene therapy, glioma, immunotherapy, review literature
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Tang, P. Flomenberg, L. Harshyne, L. Kenyon, and D. W. Andrews Glioblastoma Patients Exhibit Circulating Tumor-Specific CD8+ T Cells Clin. Cancer Res., July 15, 2005; 11(14): 5292 - 5299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Hammoud, C. J. Belden, A. C. Ho, G. J. D. Pan, E. H. Herskovits, D. C. Hilt, H. Brem, and M. G. Pomper The Surgical Bed After BCNU Polymer Wafer Placement for Recurrent Glioma: Serial Assessment on CT and MR Imaging Am. J. Roentgenol., May 1, 2003; 180(5): 1469 - 1475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Lee, S. Dallas, M. Hong, and R. Bendayan Drug Transporters in the Central Nervous System: Brain Barriers and Brain Parenchyma Considerations Pharmacol. Rev., December 1, 2001; 53(4): 569 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. H.-F. Chang, N. M. Barbaro, and R. O. Pieper Phosphatidylserine-dependent phagocytosis of apoptotic glioma cells by normal human microglia, astrocytes, and glioma cells Neuro-oncol, July 1, 2000; 2(3): 174 - 183. [Abstract] [PDF]
|
|